Kythera Biopharmaceuticals Inc (KYTH) 34.43 $KYTH
KYTHERA Biopharmaceuticals Submits New Drug Application for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
GlobeNewswire - Mon May 12, 6:30PM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ATX-101 (deoxycholic acid) as an injectable treatment for the reduction of submental fat, which commonly presents as a double chin. Positive and consistent results from two pivotal Phase III trials - REFINE-1 and REFINE-2 - were reported in late 2013 and provide the basis for the NDA submission. In these trials, the majority of ATX-101 patients had a visible reduction in fat under the chin and reported significant improvement in the visual and emotional impact of treatment.
KYTHERA Biopharmaceuticals Releases First Quarter 2014 Operating Results
GlobeNewswire - Thu May 08, 3:49PM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today reported financial results for its first quarter 2014, and provided an update on recent accomplishments.
KYTHERA Biopharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Wed May 07, 3:47PM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas.
Product Launches, Conference Call Schedules, Promotions, and Appointments - Analyst Notes on Theravance, Volcano, Steris, Cyberonics and Kythera
PR Newswire - Thu May 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Theravance Inc. (NASDAQ: THRX), Volcano Corporation (NASDAQ: VOLC), Steris Corp. (NYSE: STE), Cyberonics Inc. (NASDAQ: CYBX) and Kythera Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1881-100free.
KYTHERA Biopharmaceuticals to Release First Quarter 2014 Operating Results
GlobeNewswire - Thu Apr 24, 4:06PM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its first quarter 2014 operating results and will host an investor call and webcast at 4:30 p.m. ET on Thursday, May 8, 2014.
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Kythera Biopharmaceuticals, Inc. (KYTH) in Focus: Stock Surges 9.9 % - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:44AM CDT
Kythera Biopharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.
What Falling Estimates & Price Mean for Kythera (KYTH) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 7:57AM CDT
It may be a good decision to sell Kythera as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a Zacks Rank #4 confirms weakness.
Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma
PR Newswire - Tue Mar 25, 10:00AM CDT
On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
KYTHERA Biopharmaceuticals Announces 2013 Operating Results
GlobeNewswire - Mon Mar 17, 3:26PM CDT
KYTHERA Biopharmaceuticals, Inc.(Nasdaq:KYTH) today reported financial results for its quarter and year ended December 31, 2013, and provided an update on recent accomplishments.
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Kythera Regains ATX-101 from Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 3:39PM CDT
Kythera regained all rights to ATX-101 outside the U.S. and Canada from the HealthCare segment of Bayer.
Why KYTHERA Biopharmaceuticals Inc. Shares Shot Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 3:12PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of KYTHERA Biopharmaceuticals , a...
KYTHERA Acquires Rights to ATX-101 Outside of the U.S. and Canada From Bayer Consumer Care
GlobeNewswire - Mon Mar 10, 3:05PM CDT
KYTHERA Now Holds Global Rights to ATX-101
KYTHERA Biopharmaceuticals to Release 2013 Operating Results
GlobeNewswire - Mon Mar 10, 9:02AM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its fourth quarter and full year 2013 operating results and will host an investor call and webcast at 4:30 p.m. ET on Monday, March 17, 2014.
KYTHERA Biopharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Fri Feb 28, 3:33PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Cowen and Company 34th Annual Health Care Conference in Boston, MA.
MarketMeSuite pilots Constant Contact's Small Business Innovation Program and announces new Constant Contact integration
Business Wire - Wed Feb 19, 8:00AM CST
MarketMeSuite (MarketMeSuite.com), the leading social media management and marketing platform for small businesses and professionals, has integrated with Constant Contact, launched on Constant Contact's MarketPlace, and has been named the first technology partner to join Constant Contact's Small Business Innovation program.
Use Options For A Chance To Buy KYTH At A 17% Discount
at The Street - Wed Feb 12, 10:50AM CST
Looking back to 127 days ago, Kythera Biopharmaceuticals priced a 2,622,950 share secondary stock offering at $45.75 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over...
KYTHERA Biopharmaceuticals Submits New Drug Application for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
GlobeNewswire - Mon May 12, 6:30PM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ATX-101 (deoxycholic acid) as an injectable treatment for the reduction of submental fat, which commonly presents as a double chin. Positive and consistent results from two pivotal Phase III trials - REFINE-1 and REFINE-2 - were reported in late 2013 and provide the basis for the NDA submission. In these trials, the majority of ATX-101 patients had a visible reduction in fat under the chin and reported significant improvement in the visual and emotional impact of treatment.
KYTHERA Biopharmaceuticals Releases First Quarter 2014 Operating Results
GlobeNewswire - Thu May 08, 3:49PM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today reported financial results for its first quarter 2014, and provided an update on recent accomplishments.
KYTHERA Biopharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Wed May 07, 3:47PM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas.
Product Launches, Conference Call Schedules, Promotions, and Appointments - Analyst Notes on Theravance, Volcano, Steris, Cyberonics and Kythera
PR Newswire - Thu May 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Theravance Inc. (NASDAQ: THRX), Volcano Corporation (NASDAQ: VOLC), Steris Corp. (NYSE: STE), Cyberonics Inc. (NASDAQ: CYBX) and Kythera Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1881-100free.
KYTHERA Biopharmaceuticals to Release First Quarter 2014 Operating Results
GlobeNewswire - Thu Apr 24, 4:06PM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its first quarter 2014 operating results and will host an investor call and webcast at 4:30 p.m. ET on Thursday, May 8, 2014.
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Kythera Biopharmaceuticals, Inc. (KYTH) in Focus: Stock Surges 9.9 % - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:44AM CDT
Kythera Biopharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.
What Falling Estimates & Price Mean for Kythera (KYTH) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 7:57AM CDT
It may be a good decision to sell Kythera as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a Zacks Rank #4 confirms weakness.
Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma
PR Newswire - Tue Mar 25, 10:00AM CDT
On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
KYTHERA Biopharmaceuticals Announces 2013 Operating Results
GlobeNewswire - Mon Mar 17, 3:26PM CDT
KYTHERA Biopharmaceuticals, Inc.(Nasdaq:KYTH) today reported financial results for its quarter and year ended December 31, 2013, and provided an update on recent accomplishments.
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Kythera Regains ATX-101 from Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 3:39PM CDT
Kythera regained all rights to ATX-101 outside the U.S. and Canada from the HealthCare segment of Bayer.
Why KYTHERA Biopharmaceuticals Inc. Shares Shot Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 3:12PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of KYTHERA Biopharmaceuticals , a...
KYTHERA Acquires Rights to ATX-101 Outside of the U.S. and Canada From Bayer Consumer Care
GlobeNewswire - Mon Mar 10, 3:05PM CDT
KYTHERA Now Holds Global Rights to ATX-101
KYTHERA Biopharmaceuticals to Release 2013 Operating Results
GlobeNewswire - Mon Mar 10, 9:02AM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its fourth quarter and full year 2013 operating results and will host an investor call and webcast at 4:30 p.m. ET on Monday, March 17, 2014.
KYTHERA Biopharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Fri Feb 28, 3:33PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Cowen and Company 34th Annual Health Care Conference in Boston, MA.
MarketMeSuite pilots Constant Contact's Small Business Innovation Program and announces new Constant Contact integration
Business Wire - Wed Feb 19, 8:00AM CST
MarketMeSuite (MarketMeSuite.com), the leading social media management and marketing platform for small businesses and professionals, has integrated with Constant Contact, launched on Constant Contact's MarketPlace, and has been named the first technology partner to join Constant Contact's Small Business Innovation program.
Use Options For A Chance To Buy KYTH At A 17% Discount
at The Street - Wed Feb 12, 10:50AM CST
Looking back to 127 days ago, Kythera Biopharmaceuticals priced a 2,622,950 share secondary stock offering at $45.75 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over...
